Three new diabetic technologies have been approved by the FDA. What are they? Scroll through our slideshow to find out.
What are the new diabetes technologies on the market? We'll give you a hint: they include the first approved fully interoperable CGM system, an update to the first hybrid loop systems, and the first shock wave device approved for the treatment of diabetic foot ulcers. Click through our slideshow above for a closer look at these three diabetic techologies.Â
Dexcom G6 Continuous Glucose Monitor. The Dexcom G6 is the first approved CGM that can form an integrated system with compatible devices. The small patch contains a sensor and is applied to the skin of the abdomen to send real-time glucose readings every 5 minutes to the mobile app.
Medtronic MiniMed 630G, 670G Insulin Pump System. While the MiniMed 630G was approved in 2017 and the 670G in 2016, they now have a new indication to insert the sensor into the upper arm in addition to the abdomen. The 630G is indicated for patients aged 16 and older and the 670G is indicated for patients aged 14 and older.
For more information on the MiniMed 630G, go to: MiniMed 630G System with SmartGuard - P150001/S021
For more information on the MiniMed 670G, go to: Minimed 670G System - P160017/S017
DermaPace System. The DermaPace system is the first shock wave device approved for treating diabetic foot ulcers. It uses pulses of energy to stimulate the wound and is intended for patients aged 22 and older with foot ulcers about the size of a soda can top that last more than 30 days.
For more information, go to: FDA permits marketing of device to treat diabetic foot ulcers